Elevated level of high-sensitivity C-reactive protein is important in determining prognosis in chronic heart failure

Medical Science Monitor

Volumn 16, Issue 3, 2010, Pages

  Kozdaǧ, Güliz ^a   Ertaş, Gökhan ^a   Kiliç, Teoman ^a   Acar, Eser ^a   Aǧir, Ayşen ^a   Şahin, Tayfun ^a   Çetin, Metin ^a   Bildirici, Ulaş ^a   Ural, Dilek ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Chronic heart failure; Dilated cardiomyopathy; hs CRP; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 77649264383     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hirshfield GM, Pepys MB: C-reactive protein and cardiovascular disease: New insights from an old molecule. Q J Med, 2003; 96: 793-807
2. Pye M, Rae AP, Cobbe SM: Study of serum C-reactive protein concentration in cardiac failure. Br Heart J, 1990; 63: 228-30
3. Kaneko K, Kanda T, Yamauchi Y et al: C-reactive protein in dilated cardiomyopathy. Cardiology, 1999; 91: 215-19
4. Sato Y, Takatsu Y, Kataoka K et al: Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol, 1999; 22: 811-13
5. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI: Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J, 1996; 17: 1345-49
6. Steele IC, Nugent AM, Maguire S et al: Cytokine profile in chronic cardiac failure. Eur J ClinInvest, 1996; 26: 1018-22
7. Schiller NB, Shah PM, Crawford M et al: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr, 1989; 2: 358-67
8. Tortoledo FA, Quinones MA, Fernandez GC et al: Quantification of left ventricular volumes by two-dimensional echocardiography: a simplified and accurate approach. Circulation, 1983; 67: 579-84
9. Helmcke F, Nanda NC, Hsiung MC et al: Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation, 1987; 75: 175-83
10. Bardy GH, Lee KL, Mark DB et al: Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med, 2005; 352: 225-37
11. Mark DB, Nelson CL, Anstrom KJ et al: SCD-HeFT Investigators. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation, 2006; 114: 135-42
12. Choi H, Cho DH, Shin HH, Park JB: Association of high sensitivity C-reactive protein with coronary heart disease prediction, but not with carotid atherosclerosis, in patients with hypertension. Circ J, 2004; 68: 628-33
13. Yip HK, Hung WC, Yang CH et al: Serum concentration of high-sensitivity C-reactive protein predict progressively obstructive lesions rather than late restenosis in patients with unstable angina undergoing coronary artery stenting. Circ J, 2005; 69: 1202-7
14. Yin WH, Chen JW, Jen HL et al: Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J, 2004; 147: 931-38
15. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M et al: C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail, 2002; 4: 331-36
16. Ishikawa C, Tsutamoto T, Fujii M et al: Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ J, 2006; 70: 857-63
17. Anand IS, Latini R, Florea VG et al: C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation, 2005; 112: 1428-34
18. Levine B, Kalman J, Mayer L et al: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med, 1990; 323: 236-41
19. Rauchhaus M, Doehner W, Francis DP et al: Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation, 2000; 102: 3060-67
20. Yamauchi-Takihara K, Ihara Y, Ogata A et al: Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation, 1995; 91: 1520-24
21. Noutsias M, Seeberg B, Schultheiss HP, Kühl U: Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation, 1999; 99: 2124-31
22. Noutsias M, Pauschinger M, Schultheiss H, Kühl U: Phenotypic characterization of infiltrates in dilated cardiomyopathy - diagnostic significance of T-lymphocytes and macrophages in inflammatory cardiomyopathy. Med Sci Monit, 2002; 8(7): CR478-87
23. Verma S, Li SH, Badiwala MV et al: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation, 2002; 105: 1890-96
24. Verma S, Wang CH, Li SH et al: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation, 2002; 106: 913-19
25. Clapp BR, Hirschfield GM, Storry C et al: Inflammation and endothelial function: Direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation, 2005; 111: 1530-36
26. Vita JA, Keaney JF Jr, Larson MG et al: Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation, 2004; 110: 3604-9
27. Chong AY, Blann AD, Patel J et al: Endothelial dysfunction and damage in congestive heart failure: Relation of flow-mediated dilatation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation, 2004; 110: 1794-98
28. Katz SD, Hryniewicz K, Hriljac I et al: Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation, 2005; 111: 310-14
29. Joynt KE, Gattis WA, Hasselblad V et al: Effect of angiotensin converting enzyme inhibitors, beta blockers, statins and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol, 2004; 93: 783-85
30. Biasucci LM, Lombardi M, Piro M et al: Irbesartan significantly reduces CRP concentrations after 1 month of treatment in unstable angina. Heart, 2005; 91: 670-71
31. Yin WH, Chen JW, Jen HL et al: Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J, 2004; 147: 931-38
32. Windram JD, Loh PH, Rigby AS et al: Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J, 2007; 153: 1048-55